Predicting and monitoring heart problems in children with AML
Predicting and Monitoring for Cardiac Toxicity in Pediatric AML
['FUNDING_R01'] · CHILDREN'S HOSP OF PHILADELPHIA · NIH-11173745
This project aims to create tools that spot and track heart damage from chemotherapy in children with acute myeloid leukemia so doctors can act sooner.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CHILDREN'S HOSP OF PHILADELPHIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11173745 on ClinicalTrials.gov |
What this research studies
Researchers are using clinical records and heart imaging from children treated for AML to build prediction models that detect early chemotherapy-related heart damage. They will combine treatment dose information, echo results, and clinical data to find patterns that signal declining heart function during frontline therapy. The team plans to refine algorithms to guide more timely heart monitoring and treatment changes and to examine differences by race and ethnicity to address disparities. Ultimately these methods would help clinicians decide which children need closer cardiac follow-up during AML treatment.
Who could benefit from this research
Good fit: Children with newly diagnosed acute myeloid leukemia receiving anthracycline-containing frontline chemotherapy would be the primary candidates for these tools.
Not a fit: Adults, patients with other cancers, or children who do not receive anthracycline chemotherapy are unlikely to benefit directly from this work.
Why it matters
Potential benefit: If successful, the tools could help prevent severe heart damage by identifying high-risk children early so treatment or monitoring can be adjusted.
How similar studies have performed: Previous studies have predicted long-term heart problems in childhood cancer survivors, but predicting acute, treatment-time cardiotoxicity in newly diagnosed pediatric AML is largely new and untested.
Where this research is happening
PHILADELPHIA, UNITED STATES
- CHILDREN'S HOSP OF PHILADELPHIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: APLENC, RICHARD — CHILDREN'S HOSP OF PHILADELPHIA
- Study coordinator: APLENC, RICHARD
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Treatment